All In Biotech

Drug Trial Radar · NCT03953300

Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics

A Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

75

Actual

Start

Oct 8, 2019

Primary completion

Oct 20, 2026

Study completion Oct 20, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
May 16, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication. Patients who complete treatment will enter 4 weeks follow-up period.

Conditions

  • Asthma

Interventions

  • BenralizumabBiological

    Benralizumab: 30 mg/mL solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks - Weeks 16, 24, 32, 40.

  • PlaceboBiological

    Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks - Weeks 16, 24, 32, 40.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change in eosinophil numbers expressed as number/mm2 in submucosa as measured by major basic protein (MBP) staining in endobronchial biopsiesTime frame: From baseline to Week 48 (Visit 10)
  2. The change in airway wall area percentage as the overall median for airway generations 3 and 4 combined as measured by quantitative computed tomography (QCT) imagingTime frame: From baseline to Week 48 (Visit 10)

Locations

35 sites in 5 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Los Angeles, California

  • Research Site

    Jacksonville, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Snellville, Georgia

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Iowa City, Iowa

  • Research Site

    Kansas City, Kansas

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Bloomfield Hills, Michigan

  • Research Site

    Rochester, Minnesota

  • Research Site

    St Louis, Missouri

  • Research Site

    Maspeth, New York

  • Research Site

    New Bern, North Carolina

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Galveston, Texas

  • Research Site

    Lewisville, Texas

  • Research Site

    Mansfield, Texas

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Aalborg, Denmark

  • Research Site

    Aarhus N, Denmark

  • Research Site

    Copenhagen, Denmark

  • Research Site

    Hvidovre, Denmark

  • Research Site

    Næstved, Denmark

  • Research Site

    Odense C, Denmark

  • Research Site

    Vejle, Denmark

  • Research Site

    Gothenburg, Sweden

  • Research Site

    Lund, Sweden

  • Research Site

    Cambridge, United Kingdom

  • Research Site

    Headington, United Kingdom

  • Research Site

    Leicester, United Kingdom

  • Research Site

    Liverpool, United Kingdom

  • Research Site

    London, United Kingdom

  • Research Site

    Wythenshawe, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.